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Abstract
Glioblastoma multiforme (GBM) overexpresses interleukin 13 receptor α2 (IL-13Rα2), a tumor-restricted receptor
that is not present in normal brain. We and others have created targeted therapies that specifically eradicate tumors
expressing this promising tumor-restricted biomarker. As these therapies head toward clinical implementation, it
is critical to explore mechanisms of potential resistance. We therefore used a potent IL-13Rα2–targeted bacterial
cytotoxin to select for naturally occurring “escapee” cells from three different IL-13Rα2–expressing GBM cell lines.
We found that these side populations of escapee cells had significantly decreased IL-13Rα2 expression. We exam-
ined clinically relevant biologic characteristics of escapee cell lines compared to their parental cell lines and found
that they had similar proliferation rates and equal sensitivity to temozolomide and radiation, the standard therapies
given to GBM patients. In contrast, our escapee cell lines were less likely to form colonies in culture and migrated
more slowly in wound healing assays. Furthermore, we found that escapee cells formed significantly less neuro-
spheres in vitro, suggesting that IL-13Rα2–targeted therapy preferentially targeted the “stem-like” cell population
and possibly indicating decreased tumorigenicity in vivo. We therefore tested escapee cells for in vivo tumorigenicity
and found that theywere significantly less tumorigenic in both subcutaneous and intracranial mousemodels compared
to matching parental cells. These data, for the first time, establish and characterize the clinically relevant biologic
properties of IL-13Rα2–targeted therapy escapees and suggest that these cells may have less malignant characteristics
than parental tumors.
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Introduction
High-grade astrocytomas including anaplastic astrocytomas (World
Health Organization grade 3) and glioblastoma multiforme (GBM;
World Health Organization grade 4) are invariably fatal malignancies
despite the current standard of care that includes surgery, chemo-
therapy, and radiation therapy [1,2]. Molecular targeted therapies have
emerged as an innovative approach to eradicate tumors that express
tumor-restricted biomarkers without harming normal brain or tissue.
In past works, we found that interleukin 13 receptor α2 (IL-13Rα2)
is a high-grade astrocytoma–restricted receptor for IL-13 that is over-
expressed in greater than 70% of GBMs but not significantly expressed
in brain or normal tissues except in the testes [3–7]. Thus, we and
others have developed a number of therapeutic strategies that potently
and specifically target GBM cells expressing IL-13Rα2 [4,5,8–17]. For
example, Mintz et al. [17] and Debinski et al. [18–20] used powerful
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bacterial toxins genetically fused to targeted derivatives of IL-13 to eradi-
cate IL-13Rα2–expressing tumors. Importantly, a first generation IL-13–
based cytotoxin, IL-13–PE38QQR, has shown clinical activity in phase 1
and 2 clinical trials for GBM patients when administered locally with
convection-enhanced delivery (CED) [21–26]. Of significance, the
phase 3 Randomized Evaluation of CED of IL-13–PE38QQR with
Survival End points (PRECISE) trial demonstrated increased overall
survival of patients treated by neurosurgeons with experience
performing CED [27], although it did not reach its clinical end points
owing to a number of factors, including use of early generation sub-
optimized CED, lack of biomarker expression screening, and possibly
affinity toward the physiologically abundant IL-13Rα1/IL4Rα hetero-
dimer that is expressed on healthy brain [27–29]. However, we and
others are building on the positive findings of the PRECISE trial by
developing advanced platforms that exploit IL-13Rα2–specific ligands,
such as targeted mutants of IL-13, peptides and antibodies, which only
target the tumor-associated IL-13Rα2 [14,15,30]. Other advances in
IL-13Rα2 targeting include systemically administered therapies
[11,12,16] and diagnostic technologies that can quantitate, a priori,
IL-13Rα2 expression [31]. Furthermore, significant improvements to
CED promise to effectively increase the volume exposed to locally
delivered IL-13Rα2–targeted therapies [7,32] as it has been estimated
by new software developed after the PRECISE trial completion that
only 21.1% of the highest-risk 2-cm region surrounding the resection
cavity was covered on average in the trial [32]. Thus, as these improved
platforms are developing, it is important to examine mechanisms and
clinically relevant biologic characteristics of cells that escape targeted
IL-13Rα2 therapy.
As with other therapies, development of therapeutic resistance re-
mains a major challenge because, as cells either become or are inher-
ently resistant to a therapy, they may also become more aggressive
and be less sensitive toward standard therapeutics [33,34]. Therapeu-
tic resistance can be actively induced in cancer cells on exposure to a
specific therapeutic agent, such as when anticancer drugs are pumped
out through drug efflux pumps that can be present before therapy
and amplified directly in response to therapeutic administration. In
contrast, cancer cells may naturally not be sensitive to a particular
agent because of expression alterations that undermine a drug’s action
[35]. Examples of this passive resistance include cancer cells that
are naturally not susceptible to taxanes due to lost expression of β2-
tubulin, a protein to which they must bind to exert their anticancer
action [36], and intrinsic resistance to tumor necrosis factor–related
apoptosis-inducing ligand that is sometimes encountered due to absent
expression of functional DR4 and DR5, the death receptors that bind
tumor necrosis factor–related apoptosis-inducing ligand and induce
apoptosis in cancer cells [37]. In this work, for the first time, we selected
subpopulations of GBM cells that are naturally not susceptible to IL-
13Rα2–targeted therapy because of the lack of receptor expression.
Furthermore, we examine clinically relevant biologic properties of these
“escapee” cells as well as their susceptibility to the current standard
therapies used in the clinic to treat GBM patients.
Materials and Methods
Materials
Tissue culture equipment was from Corning Glass (Corning, NY).
SNB-19 and A-172 cell lines were purchased from American Type
Culture Collection (Manassas, VA). U-251malignant glioma (MG) cell
line was a gift fromDr. JayDorsey.MTS/PMS (3-(4,5-dimethylthiazol-
2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H -tetrazolium,
inner salt/phenazine methosulfate was purchased from Promega
(Madison, WI). Sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and Western blot transferring equipment were from Bio-Rad
(Hercules, CA) and Invitrogen (Carlsbad, CA). Primary anti–IL-13Rα2
antibody (AF146) was obtained from R&D Systems (Minneapolis,
MN), and secondary antibody was from Santa Cruz Biotechnology
(Santa Cruz, CA). IODO-GEN reagents for 125I labeling were pur-
chased from Pierce (Rockford, IL).
Selection of IL-13Rα2–Targeted Therapy Escapee Cells
To obtain subpopulations of GBM cells that are not sensitive to
IL-13Rα2–targeted therapy, we treated three different IL-13Rα2–
expressing GBM cell lines (SNB-19, A-172, and U-251) with high
doses of IL-13–based cytotoxins (10-100 ng/ml) that we previously
demonstrated to potently kill IL-13Rα2–expressing cells. Importantly,
we alternated the selection with IL-13–based Diphtheria (DT) and
IL-13–based Pseudomonas exotoxin (PE) derivatives to prevent resis-
tance to a specific type of bacterial toxin [15,38]. We also performed
similar selection on two early-passage tumor cell lines derived from
patients diagnosed with GBM that we obtained from the Wake
Forest University Brain Tumor Center of Excellence tumor depository
(BTCOE 4673 and 4682, both at passage 6).
Cytotoxicity Assay
Cytotoxicity assays were performed as described previously [15].
Briefly, 1 × 103 cells were plated on each well of a 96-well plate in
150 μl of medium and allowed to adhere overnight. The following
day, 25 μl of blocker (8 μg/ml), for example, IL-13 derivatives in
0.1% bovine serum albumin/PBS buffer, or buffer alone, was added.
After an hour of incubation at 37°C, 25 μl of varying concentrations of
IL-13–based PE or DT was added in quadruplicate and incubated at
37°C in 5% CO2/95% O2 for 48 hours. After 48 hours, MTS/PMS
cell proliferation assay was performed as instructed by the manufac-
turer (Promega). Ten microliters of dye was added to each well and
incubated for 2 to 4 hours. Plates were then read using a microplate
reader at an absorbance of 490 nm. Cyclohexamide-treated, cell-
containing wells served as the background for the assay. Background
was subtracted from each data point and was divided by the value from
the wells that were not treated with cytotoxin to obtain the fraction
of cells remaining. The fraction of cells remaining was multiplied by
100 to obtain the percent of control.
Western Blot
Western blot analysis was done as described previously [39]. Mem-
branes were incubated with primary antibody overnight at 4°C and with
secondary antibody conjugated with HRP for 1 hour at room tempera-
ture. Detection was done using the enhanced chemiluminescence plus
Western Blot Analysis Detection System (GE Healthcare, Piscataway,
NJ) with the LAS-3000 imaging system (Fujifilm) and images compiled
using Adobe Photoshop Elements 5.0 (Adobe Systems, San Jose, CA).
Lysates of early-passage cells were harvested at passage 8.
Clonogenic Assay
Cells (100 cells per well) were plated in six-well plates in triplicate in
growth medium, which was replaced with fresh medium every 3 days.
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Colonies were microscopically imaged at low power (×4 magnification)
after 14 days. Plates were then washed with PBS, fixed with methanol,
stained with crystal violet, and photographed.
Cell Proliferation Assay
A total of 1 × 103 cells per well were plated in 96-well plates in
quadruplicate for each cell line. After 24, 48, and 72 hours in culture,
proliferation was measured using a colorimetric MTS/PMS cell prolif-
eration assay as instructed bymanufacturer (Promega). Cyclohexamide-
treated cell-containing wells served as the background for the assay.
Background was subtracted from each data point and was divided by
the values obtained after 24 hours to represent fold proliferation.
Temozolomide Sensitivity Assay
A total of 1 × 103 cells per well were plated in 96-well plates in growth
medium and allowed to adhere overnight. The following day, varying
concentrations of temozolomide (TMZ; Sigma-Aldrich, St Louis, MO)
were added in quadruplicate and incubated at 37°C in 5% CO2/95%
O2 for 72 hours. After 72 hours, MTS/PMS cell proliferation assay was
performed as instructed by themanufacturer (Promega). Cyclohexamide-
treated cell-containing wells served as the background for the assay.
Background was subtracted from each data point and was divided by
the value from the wells that were not treated with TMZ to obtain the
fraction of cells remaining. The fraction of cells remaining was multi-
plied by 100 to obtain the percent of control.
Radiation Sensitivity Assay
A total of 1 × 103 cells per well were plated in 96-well plates in
growth medium and allowed to adhere overnight. The following day,
plates were subjected to varying doses of external beam irradiation or
sham control and incubated at 37°C in 5%CO2/95%O2 for 72 hours.
After 72 hours, MTS/PMS cell proliferation assay was performed as
instructed by the manufacturer (Promega). Cyclohexamide-treated,
cell-containing wells served as the background for the assay. Back-
ground was subtracted from each data point and was divided by the
value from the wells that received sham irradiation to obtain the frac-
tion of cells remaining. The fraction of cells remaining was multiplied
by 100 to obtain the percent of control.
Migration Assay
Cells were cultured in six-well plates in triplicate for each cell line
until approximately 90% confluent. Wounds were made in each
confluent monolayer of cells with a sterile 200-μl pipette tip, and
fresh growth medium was replaced. Phase-contrast microscopic pic-
tures were taken of the same field at 0, 4, 8, and 24 hours or until the
wounds were completely healed, whichever came first.
Neurosphere Formation Assay of U-251 Parental and Escapees
U-251 parental cells or escapees were resuspended in neurobasal
medium (Invitrogen) containing B27 (1×), N2 (1×), epidermal
growth factor (5 ng/ml), basic fibroblast growth factor (5 ng/ml),
and L-glutamine (5 ng/ml). Cells were then plated in 6-cm dishes
at 5 × 105 cells per dish for 7 days with fresh medium replenished
every 3 days [40–42]. Luciferin-D substrate was added (150 μg/dish),
and plates were imaged with IVIS-100 Imaging System (Caliper Life
Sciences, Hopkinton, MA). Luminescence signal was quantified using
LivingImage software accompanied the imaging system.
In Vivo Tumorigenicity of U-251 Parental and Escapees
U-251 parental and escapee cells were implanted subcutaneously
into male athymic nude (nu/nu) mice at 1 × 106 cells per mouse in
200 μl of PBS/Matrigel (BD Biosciences) as recommended by the
manufacturer. Tumor measurement was obtained weekly using a digi-
tal caliper. When tumors reached a volume exceeding 1500 mm3, mice
were killed and tumors were removed then snap frozen.
Actively growing U-251 parental and escapee cells were injected at
a concentration of 1 × 105 cells in 5 μl of PBS into the right frontal
lobe of male athymic nude (nu/nu) mice (6-8 weeks old) as previously
described [43]. Briefly, mice were anesthetized with a ketamine/
xylazine mixture (114/17 mg/kg), and a 0.5-mm burr hole was made
1 to 1.5 mm lateral of the midline and 0.5 to 1 mm posterior to the
coronal suture through a scalp incision. Stereotaxic injection at a rate
of 2 μl/min was performed on a Just For Mice stereotaxic apparatus
(Harvard Apparatus, Holliston, MA) using a 10-μl syringe (Hamilton,
Reno, NV) with a 30-gauge needle, inserted through the burr hole to a
depth of 3 mm. Animals losing ≥20% of their body weight or having
trouble ambulating or feeding were killed by transcardial perfusion.
Autoradiography
Recombinant IL-13 derivatives were labeled with 125I using
IODO-GEN method as recommended by the manufacturer (Pierce).
Autoradiography was performed as previously described [5]. Digital
detection was done using a storage phosphor screen with the Typhoon
Trio (GE Healthcare), and images were compiled using Adobe Photo-
shop Elements 5.0 (Adobe Systems).
Statistical Analyses
Statistical significance was determined by Student’s t test. Error bars
represented mean ± SD.
Results
Selection of IL-13Rα2–Targeted Therapy Escapee Cells and
Their Characterization
The escapee cell lines were established by continual passage of re-
sistant cells in growth medium supplemented with cytotoxin. After
the initial treatment, less than 5% to 10% of cells survived (Figure 1,
A-F ), but as we continued selecting these nonsensitive cells, they be-
came less responsive to either PE or DT based toxins. After passaging
for at least 8 weeks under selection conditions, all escapee cell lines
were not at all sensitive to the cytotoxin effects of both IL-13–based
PE and DT toxins (Figure 1, A-F ), suggesting an IL-13Rα2–based
resistance mechanism as opposed to resistance to an individual toxin
payload. We subsequently examined the expression of IL-13Rα2 and
found significantly decreased or absent IL-13Rα2 expression in all
three escapee cell lines compared with parental cells (Figure 1G ).
To ensure that our escapee cells were not an artifact of long-term
cell culture, we performed a similar selection strategy on two early-
passage tumor cell lines derived from patients diagnosed with GBM
(BTCOE 4673 and 4682) and found that we were also able to select
for subpopulations of cells that had significantly decreased suscep-
tibility to the IL-13Rα2–targeted cytotoxin and decreased receptor
expression (Figure 1G ).
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IL-13Rα2–Targeted Therapy Escapees Proliferate Similar
to Parental Cells and Remain Sensitive to TMZ
and Radiation
We next examined clinically relevant biologic characteristics of
escapee cell lines compared to their parental cell lines, including pro-
liferation rates and sensitivity toward TMZ and radiation therapy, the
standard of care given to newly diagnosed GBM patients [44,45]. We
analyzed the proliferation rates of all escapee cell lines and found no
significant difference of all three escapee cell lines compared to their
respective parental lines (Figure 2A). Similarly, all three escapee cell
lines demonstrated similar sensitivity to either TMZ (Figure 2B) or
radiation therapy (Figure 2C ) compared to their respective parental
lines. Importantly, these data suggest that IL-13Rα2–targeted ap-
proaches do not select for more proliferative tumor cells or tumors
that are cross resistant to standard GBM therapies, such as TMZ and
radiation therapy.
Figure 1. Susceptibility of GBM parental and escapee cells to IL-13Rα2–targeted toxins (excess amounts of IL-13Rα2–specific IL-13
mutants served as blockers in these assays and percentage of cells alive was calculated as percent A490 of untreated control). (A-C)
Cytotoxicity of IL-13–based PE toxin on (A) SNB-19 parental and escapees, (B) A-172 parental and escapees, (C) U-251 parental and
escapees. (D-F) Cytotoxicity of IL-13–based DT toxin on (D) SNB-19 parental and escapees, (E) A-172 parental and escapees, (F) U-251
parental and escapees (*P≤ .05, **P≤ .01 comparing parental and escapee cell lines). (G) Western blot for IL-13Rα2 in SNB-19, A-172,
U-251, and BTCOE 4673 and 4682 parental and escapee cell lysates. Similar to the established cell lines, BTCOE 4673 and 4682 early-
passage escapee cell lines were no longer susceptible to either IL-13–based toxin (not shown).
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IL-13Rα2–Targeted Therapy Escapees Do Not Form
Individual Colonies In Vitro
An in vitro clonogenic assay was performed on each pair of parental-
escapee GBM cell lines to compare their colony formation patterns. As
expected, all GBM parental cell lines readily formed characteristic
colonies in vitro when plated as single cells (Figure 3A). However,
the GBM escapees instead followed a disperse growth pattern as dem-
onstrated microscopically in Figure 3A. Similarly, the different colony
formation pattern was also evident macroscopically because the escapee
cell lines did not demonstrate characteristically discrete colonies when
fixed and stained (Figure 3B).
IL-13Rα2–Targeted Therapy Escapees Demonstrate
Decreased Migration
One of the most challenging issues in treating GBM is the ability
of cells to migrate/invade deep into normal brain tissue. To assess
migration rates of escapee cell lines compared to parental cells, we
used a wound healing assay. As demonstrated in Figure 4, all three
GBM escapee cell lines consistently demonstrated a lag in migration
rate compared to their parental counterparts. Because the prolifera-
tion rate of the escapee cell lines was demonstrated to be similar to
that of their corresponding parental cell lines (Figure 2A), any varia-
tion in the wound healing rate on this assay suggests divergence in cell
migration capability.
U-251 IL-13Rα2–Targeted Therapy Escapee Cells Have
Altered Ability to Form Neurospheres
It has been shown that “stem-like” tumor-initiating cells exist in
GBM, which are identified by their ability to form neurospheres
in vitro. Furthermore, it has been reported that this population of
cells express IL-13Rα2 [46] and thus may be preferentially eradicated
by molecular therapies that target IL-13Rα2, resulting in less tumori-
genic cells in vivo. We therefore investigated whether our subpopu-
lation of escapee cells is stripped of their ability to effectively form
neurospheres in vitro and tumors in vivo. We examined the neuro-
sphere formation potential of U-251 escapee cells compared to their
parental cell line because these are the most tumorigenic of the three
analyzed parental cell lines. Our data demonstrated that U-251 escapee
Figure 2. Proliferation (A), TMZ sensitivity (B), and radiation sensitivity (C) determined in a colorimetric cell assay by SNB-19 parental and
escapee cells, A-172 parental and escapee cells and U-251 parental and escapee cells. No significant statistical difference in proliferation
and sensitivity to TMZ was observed between matching parental and escapee cells at any time point. No consistent significant differ-
ence in sensitivity to radiation was observed across the parental and matching escapee cell lines examined.
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cells had a significantly decreased ability to form neurospheres in vitro
compared to their matching parental cells (Figure 5, A and B). To sup-
port the notion that IL-13Rα2–targeted therapy effectively targets
tumor-initiating “stem-like” cells, we treated parental U-251 neuro-
spheres with an IL-13–based bacterial toxin that we used in our selec-
tion process to obtain the escapee cells. Importantly, we found that the
IL-13Rα2–targeted toxin effectively eradicated neurospheres formed
from parental U-251 cells (Figure 5, C and D).
IL-13Rα2–Targeted Therapy Escapees Are Less
Tumorigenic In Vivo
On the basis of the differences shown above between IL-13Rα2–
targeted therapy escapees and their parental cell lines, we examined
the tumorigenicity of the U-251 escapees compared to parental U-251
cells. As expected, parental U-251 cells successfully initiated tumor for-
mation and mice became morbid with tumor burden at approximately
35 days after implantation. In contrast, mice implanted with U-251
escapees cells remained healthy with very small or no palpable tumors
present (Figure 6A). In the rare events that the U-251 escapees did
initiate a tumor, the formation was significantly delayed.
We further examined the tumorigenicity of escapee cells in an in-
tracranial murine model by stereotactically injecting either U-251
escapee or matching parental cells in the right frontal lobe of athymic
nude mice. Similar to the subcutaneous tumors, the U-251 escapee
cells were less aggressive, and mice injected with these cells demon-
strated prolonged survival compared to those injected with matching
parental cells (Figure 6B). This increased survival seemed to be due
to both a delay in tumor formation and a decreased proliferation. At
day 15 after stereotactic implantation, bioluminescence imaging
demonstrated enhanced signals in all mice implanted with parental
U-251 cells but not in mice injected with escapee cells (Figure 6C ).
Furthermore, when following tumor growth in individual mice, we
found that in mice implanted with U-251 parental cells, enhanced bio-
luminescence signal was readily detected as early as day 13 and rapidly
progressed in contrast to mice implanted with escapee cells (Figure 6D).
Importantly, receptor expression studies using autoradiography on
the escapee tumor specimens demonstrated no significant functional
IL-13Rα2 expression, similar to the implanted cells and demonstrating
that IL-13Rα2 was not reexpressed in these tumors (Figure 6E ).
Discussion
In this work, for the first time, we established and characterized
IL-13Rα2–targeted therapy escapee cells from three established GBM
cell lines. This new knowledge is increasingly important owing to
Figure 3. Colony formation by SNB-19, A-172, and U-251 parental and escapee cells. (A) Representative microscopic appearance of
colonies formed by each cell line or lack thereof. (B) Macroscopic appearance of U-251 parental (upper panel) and escapee (lower panel)
clonogenic plates.
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the spreading interest in developing therapeutic platforms that target
IL-13Rα2, including active and passive immunotherapy, gene therapy,
targeted viruses, and nanotherapy [8,14,16,30,31]. We therefore iso-
lated escapee cell populations by using IL-13–based bacterial cytotoxins
that we and others had previously shown to potently and specifically kill
IL-13Rα2–expressing cells [15,17,47]. We found subpopulations of
GBM cell lines and early-passage tumor cell cultures that were not sus-
ceptible to targeted cytotoxin because they expressed significantly less
Figure 4.Migration determined in a wound healing assay by (A) SNB-19 parental and escapee cells, (B) A-172 parental and escapee cells,
and (C) U-251 parental and escapee cells.
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IL-13Rα2. Of potential clinical significance, all three escapee lines were
similar to their parental counterparts in terms of proliferation rate and
sensitivity to TMZ and radiation, the standard of care given to patients
with newly diagnosed GBM. Importantly, we found that the escapee
cell lines had a significantly decreased ability to form colonies or migrate
in vitro. Furthermore, escapee cells demonstrated significantly dimin-
ished neurosphere formation in vitro, which was concordant with our
in vivo data that revealed decreased tumorigenicity of escapee cells in
subcutaneous and orthotopic models. We postulate that this lower
tumorigenicity can potentially be attributed to the escapees’ limited
tumor initiation capability, or possibly lack of “stemness,” as demon-
strated by their decreased neurosphere formation. This would be in
agreement with other published data that indicate IL-13Rα2 expression
on CD133+ stem-like cells [46].
We hypothesize that we are selecting for a preexisting population
of IL-13Rα2 escapee cells rather than cells that actively downregulate
IL-13Rα2 during selection because the toxins that we used in the
selection process are highly potent and have been reported to kill
even if only a few molecules of bacterial toxin have access to a cell
through IL-13Rα2. Such potency would give the cell little chance to
downregulate the receptor once it has been exposed to the toxin. Fur-
thermore, the escapee cells remained not susceptible to targeted ther-
apy with significantly decreased IL-13Rα2 expression even months
after we stopped the selection process, which argues against a more
fluid regulation of IL-13Rα2.
Whereas these initial escapee cells were isolated from early-passage
and established cell lines in vitro, our findings suggest for the first
time that IL-13Rα2–targeted therapy escapees from a heterogeneous
GBM tumor may belong to an independent intrinsic subpopulation
that lacks significant expression of the IL-13Rα2 biomarker and dem-
onstrates distinct tumor biology both in vitro and in vivo. Importantly,
we are following up this work by confirming our results on IL-13Rα2–
negative cells isolated directly from patient’s tumor specimens com-
pared to matching IL-13Rα2–positive cells from the same tumor. In
addition, we are further evaluating a possible functional role played
by IL-13Rα2, which can explain the decreased colony formation and
migration patterns in vitro in the escapee population. An alternative
scenario is one in which we merely selected for a separate population
of cells with different characteristics and receptor expression profiles.
As GBM management remains focused on molecular biomarker-
targeted therapies, it is critical to identify mechanisms of potential
resistance. This will allow us to develop preventative measures such
as combinatorial therapy with other modalities. The evidence pres-
ented here suggests that a mechanism of how subpopulations of
GBM cells avoid being killed by IL-13Rα2–targeted therapy is through
decreased IL-13Rα2 receptor expression. Importantly, these IL-
13Rα2–resistant cells remain equally susceptible to chemotherapy
and radiation therapy but less tumorigenic in our models. Thus, this
first report on the existence of IL-13Rα2–targeted therapy escapee
populations suggests the significance of combinatorial approaches to
Figure 5. (A) Microscopic appearance (4×) of representative neurospheres formed by U-251 parental and escapee cells. (B) Quantifica-
tion of luminescent signals from entire dishes of growing neurospheres represented in A. (C) Microscopic appearance of neurospheres
formed by U-251 parental cells in the absence and presence of IL-13–based bacterial toxin (IL-13–DT) that targets IL-13Rα2. (D) Quan-
tification of luminescent signals from entire dishes of growing neurospheres represented in C (**P ≤ .01).
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Figure 6. In vivo tumorigenicity of U-251 parental and escapee cells. (A) Subcutaneous tumor growth in nude mice (*P≤ .05, **P ≤ .01).
(B) Survival by nude mice after intracranial implantation of U-251 parental and escapee tumors. (C) Bioluminescence image of mice
implanted with U-251 parental and escapee cells at day 15 after injection. (D) Bioluminescence image of a representative mouse from
each intracranially implanted group from day 1 to day 34 after injection. (E) 125I-labeled IL-13 derivatives binding to U-251 parental and
escapee subcutaneous tumor snap-frozen sections via autoradiography.
398 IL-13Rα2–Targeted Therapy Escapees Nguyen et al. Translational Oncology Vol. 4, No. 6, 2011
eradicate these resistant but potentially less tumorigenic subpopulation
of escapee cells. Our results support the plans for aggressive treatments
directed at IL-13Rα2.
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